Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT)

Clinical trials for rare neuromuscular diseases imply, among other investments, a high emotional burden for the whole disease community. Translation of data from preclinical studies to justify any clinical trial must be carefully pondered in order to minimize the risk of clinical trial withdrawal or...

Descripción completa

Detalles Bibliográficos
Autores principales: Willmann, Raffaella, Lee, Joanne, Turner, Cathy, Nagaraju, Kanneboyina, Aartsma-Rus, Annemieke, Wells, Dominic J., Wagner, Kathryn R., Csimma, Cristina, Straub, Volker, Grounds, Miranda D., De Luca, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044444/
https://www.ncbi.nlm.nih.gov/pubmed/32066568
http://dx.doi.org/10.1242/dmm.042903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044444/
https://www.ncbi.nlm.nih.gov/pubmed/32066568
http://dx.doi.org/10.1242/dmm.042903

Ejemplares similares